Based on the evidence, I predict that CAR T cells manufactured with Interleukin-15 will exhibit a significantly higher and more sustained release of pro-inflammatory cytokines, such as IFN-γ and TNF-α, upon antigen stimulation compared to CAR T cells manufactured without Interleukin-15.